IP Library Granted Patent US 10,716,804
Granted Patent B2
US 10,716,804 · App. 16/536,779 · Granted Jul 21, 2020

Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease

Inventor: Sho Funayama (Tokyo, JP)
Assignee: SEIKAGAKU CORPORATION
A61K31/738A61K9/0048A61K9/08A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,716,804
App. No.
16/536,779
Granted
Jul 21, 2020
Kind
B2
Abstract

Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

Claims (14)

1. A method for producing a cross-linked chondroitin sulfate or a pharmaceutically acceptable salt thereof, the method comprising:

reacting a chondroitin sulfate or pharmaceutically acceptable salt thereof with an amine having two or more primary amino groups in a solvent comprising a condensing agent to obtain the crosslinked chondroitin sulfate or a pharmaceutically acceptable salt thereof,

wherein a mole equivalent of the amine is from 0.005 to 0.250 relative to 1.00 mole equivalent of disaccharide unit of the chondroitin sulfate or pharmaceutically acceptable salt thereof, and

wherein the amine has a biodegradable moiety represented by the following formula (II) in a main chain thereof:

—C(═O)-D-  (II)

wherein, in the formula (II), D represents an oxygen atom or a sulfur atom.

2. The method according to claim 1 , wherein a percent of cross-linking of the cross-linked chondroitin sulfate or the pharmaceutically acceptable salt thereof is from 0.01% to 30%.

3. The method according to claim 2 , wherein the percent of cross-linking of the cross-linked chondroitin sulfate or the pharmaceutically acceptable salt thereof is from 0.05% to 10%.

4. The method according to claim 3 , wherein the percent of cross-linking of the cross-linked chondroitin sulfate or the pharmaceutically acceptable salt thereof is from 0.1% to 5%.

5. The method according to claim 1 , wherein the condensing agent is 4-(4, 6-dimethoxy-1, 3, 5-triazin-2-yl)-4-methylmorpholinium chloride.

6. The method according to claim 1 , wherein a mole equivalent of the condensing agent is from A, wherein A=0.05×valence of the amine, to B, wherein B=5.00×valence of the amine, relative to 1.00 mole equivalent of the amine.

7. The method according to claim 1 , wherein the solvent is water or a mixture of water and a water-miscible organic solvent.

8. The method according to claim 7 , wherein the water-miscible organic solvent is at least one selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, tertiary butanol, ethylene glycol monomethyl ether, ethyleneglycol monoethyl ether, acetone, 1,4-dioxane, tetrahydrofuran and acetonitrile.

9. The method according to claim 1 , wherein the amine is a diamine.

Priority Claims (2)
JP 2015-007072 · Jan 16, 2015 · national
JP 2015-150976 · Jul 30, 2015 · national
Continuity (2)
Continuation 15543748
Related Publication 20190365796A1 · Dec 5, 2019
Cited By (2)
US 12,310,981 US 12,440,510